- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Lung scanning OK widens Imatron’s EBT market
Imatron plans to use its electron beam tomography scanner to perform low-dose, single-breath-hold imaging of the entire lung. The FDA cleared the lung scanning application of Imatron’s EBT unit earlier this month.EBT scanning is three to five times
Imatron plans to use its electron beam tomography scanner to perform low-dose, single-breath-hold imaging of the entire lung. The FDA cleared the lung scanning application of Imatrons EBT unit earlier this month.
EBT scanning is three to five times faster than rotating or spiral CT scanners, and much costlier. This market clearance gives Imatron another use for its EBT technology at a time when the cheaper multislice CT has been eating into the companys position with coronary calcium screening.
Imatron has about 60 of its C150XP EBT scanners in place for coronary scanning in centers around the world.
Most people buy our scanner for the calcium scanning, said Jeff Sorenson, Imatrons director of marketing. It was originally designed to image the heart, then was converted to radiography. Our business focus is wellness applications: coronary calcium, electron beam angiography, lung scanning, and colonoscopy.
Imatron is specifically cleared for the first three. Lung scanning is being prescribed for patients who are suspected of having pulmonary emboli, pneumonia, or cancerous lung nodules. Many of the same patients are referred for coronary scanning, according to Imatron product manager David Hill.
I think (the 510(k) clearance for lung scanning) will help us competitively, Hill said, but we still think coronary calcium scanning by EBT is the best. Multislice CT (results are) not as reproducible, because it is not as fast.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
